Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia
Authors:
- On Behalf Of The Groupe D’eTude Immunologique Des Leucémies (Geil)O(On Behalf Of The Groupe D’eTude Immunologique Des Leucémies (Geil)
- 5 February 2019
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 33 (7) , 1814-1816
Abstract
No abstract availableFunding Information
- Institut National Du Cancer (STIC 2006)
This publication has 9 references indexed in Scilit:
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyBlood, 2018
- Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemiaHematological Oncology, 2017
- Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyAmerican Journal of Hematology, 2016
- Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemiaLeukemia, 2015
- Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemiaJournal of Hematology & Oncology, 2015
- Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupHaematologica, 2013
- Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemiaCancer, 2012
- Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS studyLeukemia, 2008
- Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrowHaematologica, 2007